Cytoplasmic γ-actin expression in diverse animal models of muscular dystrophy
Received 19 December 2006; received in revised form 26 February 2007; accepted 5 March 2007.
Abstract
We recently showed that cytoplasmic γ-actin (γcyto-actin) is dramatically elevated in striated muscle of dystrophin-deficient mdx mice. Here, we demonstrate that γcyto-actin is markedly increased in golden retriever muscular dystrophy (GRMD), which better recapitulates the dystrophinopathy phenotype in humans. γcyto-Actin was also elevated in muscle from α-sarcoglycan null mice, but not in several other dystrophic animal models, including mice deficient in β-sarcoglycan, α-dystrobrevin, laminin-2, or α7 integrin. Muscle from mice lacking dystrophin and utrophin also expressed elevated γcyto-actin, which was not restored to normal by transgenic overexpression of α7 integrin. However, γcyto-actin was further elevated in skeletal muscle from GRMD animals treated with the glucocorticoid prednisone at doses shown to improve the dystrophic phenotype and muscle function. These data suggest that elevated γcyto-actin is part of a compensatory cytoskeletal remodeling program that may partially stabilize dystrophic muscle in some cases where the dystrophin–glycoprotein complex is compromised.
aDepartment of Physiology, University of Wisconsin, Madison, WI, United States
bCollege of Veterinary Medicine and Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, United States
cWellcome Trust Centre for Cell-Matrix Research, University of Manchester, Manchester, UK
dDepartment of Cell and Developmental Biology, University of Illinois, Urbana, IL, United States
Corresponding author. Address: Department of Biochemistry, Molecular Biology & Biophysics, University of Minnesota, 6-155 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, United States. Tel.: +1 612 626 6517; fax: +1 612 625 2163.